Hong Keun Sik, Kim Yang Ki, Bae Hee Joon, Nam Hyo Suk, Kwon Sun U, Bang Oh Young, Cha Jae Kwan, Yoon Byung Woo, Rha Joung Ho, Lee Byung Chul, Park Jong Moo, Park Man Seok, Lee Jun, Choi Jay Chol, Kim Dong Eog, Lee Kyung Bok, Park Tai Hwan, Lee Ji Sung, Kim Seong Eun, Lee Juneyoung
Department of Neurology, Ilsan Paik Hospital, Inje University, Goyang, Korea.
Department of Medicine, Soonchunhyang University Hospital, Seoul, Korea.
J Clin Neurol. 2017 Jul;13(3):273-280. doi: 10.3988/jcn.2017.13.3.273.
The quality of anticoagulation is critical for ensuring the benefit of warfarin, but this has been less well studied in Korean ischemic stroke patients with atrial fibrillation (AF).
This study retrospectively analyzed the data of patients who had an AF-related ischemic stroke and were treated with long-term warfarin therapy in 16 Korean centers. The quality of warfarin therapy was primarily assessed by the time in therapeutic range [TTR; international normalized ratio (INR), 2.0-3.0] and additionally by the proportion of INR values within the therapeutic range.
The long-term warfarin-treated cohort comprised 1,230 patients. They were aged 70.1±9.7 years (mean±SD), 42.5% were female, and their CHA₂DS₂-VASc score was 4.75±1.41. The TTR analysis included 33,941 INR measurements for 27,487 months: per patients, 27.6 (SD, 22.4) INR measurements for 22.4 (SD, 12.9) months. The mean TTR of individual patients was 49.1% (95% confidence interval, 47.9-50.3%), and the TTR quartiles were <34.5, 34.5-49.1, 49.1-64.5%, and >64.5%. None of the 16 centers achieved a mean TTR of >60%. Of all INR measurements, 44.6% were within the therapeutic range, 41.7% were <2.0, and 13.7% were >3.0.
In Korean ischemic stroke patients who had AF, the quality of warfarin therapy was low and might be inadequate to effectively prevent recurrent stroke or systemic embolism.
抗凝质量对于确保华法林的疗效至关重要,但在韩国合并心房颤动(AF)的缺血性脑卒中患者中,这方面的研究较少。
本研究回顾性分析了16个韩国中心接受长期华法林治疗的AF相关缺血性脑卒中患者的数据。华法林治疗质量主要通过治疗范围内时间(TTR;国际标准化比值(INR),2.0 - 3.0)进行评估,此外还通过INR值在治疗范围内的比例进行评估。
长期接受华法林治疗的队列包括1230例患者。他们的年龄为70.1±9.7岁(均值±标准差),42.5%为女性,CHA₂DS₂ - VASc评分为4.75±1.41。TTR分析包括27487个月内的33941次INR测量:每位患者平均有27.6次(标准差,22.4)INR测量,持续22.4个月(标准差,12.9)。个体患者的平均TTR为49.1%(95%置信区间,47.9 - 50.3%),TTR四分位数分别为<34.5%、34.5 - 49.1%、49.1 - 64.5%和>64.5%。16个中心均未达到平均TTR>60%。在所有INR测量中,44.6%在治疗范围内,41.7%<2.0,13.7%>3.0。
在韩国合并AF的缺血性脑卒中患者中,华法林治疗质量较低,可能不足以有效预防复发性脑卒中或全身性栓塞。